Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
The EAPC has established a new Task Force on Cardiovascular Risk Factors to standardize clinical practice, improve quality of care, and address the growing global burden of cardiovascular disease.
Within the past century, the global landscape of cause-specific mortality patterns has changed dramatically: while infectious diseases were the leading cause of death before the development of antibiotics and vaccines, currently most deaths worldwide are attributable to cardiovascular (CV) disease (CVD). According to the latest statistics, CVD accounts for 45% of all deaths in women and 39% of all deaths in men within European Society of Cardiology (ESC) member countries.1 Alarmed by the rising prevalence of CVD, the medical community soon realized that atherosclerosis—the main substrate of ischaemic heart disease, stroke, and other CVD manifestations—does not occur in an unpredictable, random manner but is largely driven by underlying risk factors. In a seminal report in 1957, the Framingham study first described that high blood pressure, high cholesterol levels, and overweight are significantly associated with the development of new-onset coronary heart disease2; a few years later, a strong link to smoking and physical inactivity was also reported.3 More recently, the INTERHEART study was able to show that nine easily measured CV risk factors are associated with more than 90% of the risk of an acute myocardial infarction worldwide; these include abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, nutritional factors (consumption of fruits, vegetables, and alcohol), and absence of regular physical activity.4 Following decades of intensive basic and clinical research,5 our enhanced understanding of the central role of CV risk factors in the pathogenesis of atherosclerosis has translated into effective interventions for CVD prevention and treatment. On the one hand, risk scores and algorithms incorporating different risk factor profiles were developed to estimate (albeit with certain limitations) an individual’s likelihood of developing new-onset CVD or suffering from a recurrent CVD event.6,7 On the other hand, appropriate pharmacological therapies and non-pharmacological interventions targeting modifiable risk factors have been tested and proven to substantially reduce CV morbidity and mortality.8 Lifestyle changes, including smoking cessation, healthy nutrition, and physical activity, are now being considered essential measures for the prevention of CVD events. Importantly, our armamentarium of pharmacological interventions has been enriched with potent drugs to effectively lower blood pressure, glucose, and atherogenic lipid levels—ranging from broadly accessible, now generically available medications to novel treatments that can lower lipids to neonatal levels9 or exert cardioprotective effects far beyond their main glucose-lowering properties.10 Notably, the high costs of certain novel medications are not fully covered by health insurers in some countries, putting large populations at disadvantage and creating inequalities in CVD prevention that absolutely need to be addressed. Beyond traditional CV risk factors, psychosocial, socioeconomic, and environmental factors as well as gender-related factors (e.g. gestational diabetes or pre-eclampsia) and non-CV co-morbidities (ranging from sleep disorders across inflammatory conditions to cancer) are increasingly appreciated as major drivers of CVD risk.8 In a broader perspective, growing appreciation of the long-term sequelae of lifelong exposure to CV risk factors11,12 has shifted the focus towards earlier and more personalized interventions, aiming to maintain ideal risk factor levels throughout life and halt the progression of atherosclerosis more effectively. A PubMed search for ‘CV risk factors’ shows a sharp rise from 3967 papers in 2000 to 21 170 publications in 2020, indicating an ever-growing scientific interest in the field. With more knowledge on the clinical relevance of CV risk factors and more effective treatments available, where do we stand today? A fall in CVD rates was indeed observed in the past decades in several (particularly high-income) countries. However, CVD burden continues to rise in most lower- and mid-income countries, and alarmingly, it has begun to rise in high-income regions where it was previously declining.13 Importantly, a rise in the prevalence of obesity and diabetes—which have reached epidemic levels worldwide—has emerged as a major challenge to achieving further reductions in CVD burden globally. Moreover, with ageing of the population and population growth, the number of adults worldwide affected by arterial hypertension increased from 2.18 to 4.06 billion from 1990 to 2019.13 Despite drastic measures in many countries, global smoking prevalence was 33.5% among men and 6.8% among women in 2019; with more than 1 billion active smokers, the tobacco epidemic remains a key challenge to global CV health.13 Although effective treatments to help smoking cessation are available, only few smokers receive advice according to current guidelines—in part due to confusion caused by conflicting evidence concerning new devices such as e-cigarettes.14,15 Management of CV risk factors is suboptimal even in the context of secondary prevention, where the risk of CV events is highest and the absolute benefit achievable by effective risk factor treatment is greatest; the EUROASPIRE survey is one of many studies showing that the proportion of patients with established CVD reaching recommended treatment goals remains unacceptably low.16,17 Overall, despite major advances, management of CV risk factors remains far from optimal, creating a crucial unmet need in primary and secondary CVD prevention. Cardiovascular prevention has become a major focus of the ESC, along the lines of its primary goal to reduce the burden of CVD. The leadership of the European Association of Preventive Cardiology (EAPC) has outlined its vision to expand awareness that EAPC is ‘The Risk Factor Association’ and to bring topics like hypertension, diabetes, dyslipidaemia, and smoking to the forefront of attention.18 A key aim has been to formalize Preventive Cardiology as a subspecialty in Cardiology, in order to set standards for clinical practice and improve quality of care for our patients.17 Importantly, the European Core Curriculum for Preventive Cardiology was recently published19 in order to help standardize, structure, deliver, and evaluate training in preventive cardiology across Europe and form the basis for dedicated fellowship programmes and an EAPC subspecialty certification for cardiologists. In this context, comprehensive risk factor treatment, integrating pharmacological and lifestyle approaches, is a key EAPC strategy and remains the ultimate goal. Given the growing appreciation of the importance of optimal CV risk factor management as an effective way of reducing CVD-related morbidity and mortality, the EAPC has now launched a new Task Force on CV Risk Factors. This Task Force aims to act as an expert group on classical and non-traditional CV risk factors in the following context (Table 1) Aims of the EAPC Task Force on CV Risk Factors Provide statements focusing on evidence related to risk factor management, and advise on CV risk factors within various EAPC activities Summarize evidence on emerging treatments and identify gaps in the available evidence Identify reasons for non-adherence to guideline recommendations with regards to risk factor management and design, pilot, and evaluate interventions to improve patient care Contribute to scientific sessions and tracks in ESC and EAPC conferences, and ensure proper representation of topics related to CV risk factors in ESC Preventive Cardiology conferences by advising the respective Congress Program Committee Identify experts for each risk factor to act as speakers and contributors in EAPC educational activities (webinars) in cooperation with relevant partners Interact and collaborate with other ESC Associations, Working Groups, and Councils, building a network on issues related to CV risk factors Contribute to the development of knowledge in the field, providing comments on ESC Clinical Practice Guidelines with respect to CV risk factor management (‘How-to’ articles) Advise on CV risk factors for advocacy-related issues Contribute to scientific research projects related to the goals of this Task Force Provide statements focusing on evidence related to risk factor management, and advise on CV risk factors within various EAPC activities Summarize evidence on emerging treatments and identify gaps in the available evidence Identify reasons for non-adherence to guideline recommendations with regards to risk factor management and design, pilot, and evaluate interventions to improve patient care Contribute to scientific sessions and tracks in ESC and EAPC conferences, and ensure proper representation of topics related to CV risk factors in ESC Preventive Cardiology conferences by advising the respective Congress Program Committee Identify experts for each risk factor to act as speakers and contributors in EAPC educational activities (webinars) in cooperation with relevant partners Interact and collaborate with other ESC Associations, Working Groups, and Councils, building a network on issues related to CV risk factors Contribute to the development of knowledge in the field, providing comments on ESC Clinical Practice Guidelines with respect to CV risk factor management (‘How-to’ articles) Advise on CV risk factors for advocacy-related issues Contribute to scientific research projects related to the goals of this Task Force Aims of the EAPC Task Force on CV Risk Factors Provide statements focusing on evidence related to risk factor management, and advise on CV risk factors within various EAPC activities Summarize evidence on emerging treatments and identify gaps in the available evidence Identify reasons for non-adherence to guideline recommendations with regards to risk factor management and design, pilot, and evaluate interventions to improve patient care Contribute to scientific sessions and tracks in ESC and EAPC conferences, and ensure proper representation of topics related to CV risk factors in ESC Preventive Cardiology conferences by advising the respective Congress Program Committee Identify experts for each risk factor to act as speakers and contributors in EAPC educational activities (webinars) in cooperation with relevant partners Interact and collaborate with other ESC Associations, Working Groups, and Councils, building a network on issues related to CV risk factors Contribute to the development of knowledge in the field, providing comments on ESC Clinical Practice Guidelines with respect to CV risk factor management (‘How-to’ articles) Advise on CV risk factors for advocacy-related issues Contribute to scientific research projects related to the goals of this Task Force Provide statements focusing on evidence related to risk factor management, and advise on CV risk factors within various EAPC activities Summarize evidence on emerging treatments and identify gaps in the available evidence Identify reasons for non-adherence to guideline recommendations with regards to risk factor management and design, pilot, and evaluate interventions to improve patient care Contribute to scientific sessions and tracks in ESC and EAPC conferences, and ensure proper representation of topics related to CV risk factors in ESC Preventive Cardiology conferences by advising the respective Congress Program Committee Identify experts for each risk factor to act as speakers and contributors in EAPC educational activities (webinars) in cooperation with relevant partners Interact and collaborate with other ESC Associations, Working Groups, and Councils, building a network on issues related to CV risk factors Contribute to the development of knowledge in the field, providing comments on ESC Clinical Practice Guidelines with respect to CV risk factor management (‘How-to’ articles) Advise on CV risk factors for advocacy-related issues Contribute to scientific research projects related to the goals of this Task Force There is a currently unmet need to further increase awareness of the importance of optimal risk factor control among patients as well as health care professionals, incorporating multidisciplinary, patient-centred approaches. Poor adherence to healthy lifestyle behaviours and preventive medications remains common, resulting in suboptimal treatment and poor prognosis; in this respect, the need to enhance physician-patient communication, engage patients, and motivate behavioural changes in the context of community-based actions is increasingly appreciated.20 From a healthcare professional perspective, therapeutic inertia remains an issue, creating the need to further motivate general practitioners in primary care as well as CV specialists (including specialized nurses, general cardiology, and preventive cardiology physicians) to pursue guideline-recommended treatment targets. Joining forces with relevant partners both within and outside the EAPC and ESC, this Task Force aims to make a meaningful contribution in the ongoing battle for better risk factor management and more effective CVD prevention in Europe and beyond. Conflict of interest: None declared. Risk Factor Task Force of the European Association of Cardiology Paul Dendale, Executive Officer; Roberto Pedretti, Task Force Chair; Maryam Kavousi, Task Force Secretary; Scott Bowen; Véronique Cornelissen; Irene Gibson; Konstantinos Koskinas; Aneil Malhotra; Elena Osto; Kai Savonen; Anne Grete Semb; David R Thompson; Heinz Voeller; Donata Kurpas; Stefano Caselli; Tobias Raupach.
No takes yet. Share an insight, caveat, or question.
Koskinas et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: